Hitting the bullseye with a nonlethal payload: resistance in CD123-positive malignancies
Open Access
- 14 October 2019
- journal article
- editorial
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 129 (11), 4590-4592
- https://doi.org/10.1172/jci132443
Abstract
The interleukin 3 receptor (CD123) is a transmembrane protein that is absent or hardly expressed on normal hematopoietic stem cells, but highly expressed on the surface of cancer cells in several hematologic malignancies. In this issue of the JCI, Togami et al. investigated the mechanism of resistance to the recently approved anti-CD123 agent tagraxofusp, which consists of interleukin 3 fused to a truncated diphtheria toxin (DT) molecule. The authors demonstrated that loss of the intracellular target for DT, diphthamide, a conservative modification of histidine 715 in eukaryotic elongation factor 2, resulted in tagraxofusp resistance. Specifically, hypermethylation of the DPH1 gene, encoding a key enzyme in diphthamide synthesis, resulted in diphthamide loss. Notably, treatment with a DNA hypomethylating agent restored DPH1 expression and resensitized cells to tagraxofusp. The recognition of this resistance mechanism may have important clinical implications and lead to the development of more effective multiagent therapies.Keywords
This publication has 12 references indexed in Scilit:
- DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistanceJCI Insight, 2019
- Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell NeoplasmThe New England Journal of Medicine, 2019
- Structural Insights into the Role of Diphthamide on Elongation Factor 2 in mRNA Reading-Frame MaintenanceJournal of Molecular Biology, 2018
- Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 ImmunotherapyCancer Discovery, 2015
- Loss of diphthamide pre-activates NF-κB and death receptor pathways and renders MCF7 cells hypersensitive to tumor necrosis factorProceedings of the National Academy of Sciences of the United States of America, 2015
- CD 123 is a membrane biomarker and a therapeutic target in hematologic malignanciesBiomarker Research, 2014
- Extended diagnostic criteria for plasmacytoid dendritic cell leukaemiaBritish Journal of Haematology, 2009
- Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies.2001
- Identification of a leukemic counterpart of the plasmacytoid dendritic cellsBlood, 2001
- The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cellsLeukemia, 2000